Lumryz
(Non-extended-release oxybates)Small molecule
Jazz Pharmaceuticals0
Indications
1
Total Trials
1
Active Trials
0
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
42
Patents
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[3]
Jul 17, 2002
XYREM
NDA NDA021196
May 1, 2023
LUMRYZ
NDA NDA214755
Sources
References
- [1]
- [2]
- [3]
- [4]FDA Orange Book — Patent and exclusivity data for Lumryz. U.S. Food & Drug Administration.
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
Patent Landscape[4]
Patent Cliff
Mar 15, 2033
Earliest patent expiration — generic entry possible after this date
Patent #Expires
9050302Mar 15, 2033
10864181Mar 15, 2033
8772306Mar 15, 2033
9486426Mar 15, 2033
10213400Mar 15, 2033
37 more patents
9486426*PEDSep 15, 2033
9050302*PEDSep 15, 2033
10213400*PEDSep 15, 2033
8772306*PEDSep 15, 2033
11253494*PEDSep 15, 2033
10864181*PEDSep 15, 2033
11896572Jul 21, 2037
11839597Jul 21, 2037
12109186Jul 21, 2037
11766418Jul 21, 2037
11065224Jul 21, 2037
10272062Jul 21, 2037
12226377Jul 21, 2037
12115143Jul 21, 2037
12115144Jul 21, 2037
12115142Jul 21, 2037
11504347Jul 21, 2037
10973795Jul 21, 2037
12097175Jul 21, 2037
12115145Jul 21, 2037
12144793Jul 21, 2037
11052061Jul 21, 2037
10736866Jul 21, 2037
12138239Jul 21, 2037
12303478Jul 21, 2037
11602513Jul 21, 2037
11602512Jul 21, 2037
11400065Jul 21, 2037
11000498Jul 21, 2037
12128021Jul 21, 2037
11986451Jul 21, 2037
10952986Jul 21, 2037
11826335Jul 21, 2037
12097176Jul 21, 2037
10925844Feb 28, 2040
11583510Feb 7, 2042
11779557Mar 16, 2042